A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Two-Period Crossover Study to Investigate the Bronchodilatory Effect of 50 µg NVA237 Inhaled Once Daily in Patient With Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Two-Period Crossover Study to Investigate the Bronchodilatory Effect of 50 µg NVA237 Inhaled Once Daily in Patient With Chronic Obstructive Pulmonary Disease (COPD).

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Glycopyrrolate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 22 Sep 2010 Results were presented at the 20th Annual Congress of the European Respiratory Society.
    • 18 May 2010 Results have been presented at the 106th International Conference of the American Thoracic Society.
    • 16 Sep 2009 Actual patient number (33) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top